Orgenesis Inc. R&D Expenses

R&D Expenses of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including R&D Expenses growth rates and interactive chart. Research and development (R&D) expenses are associated with the research and development of a company's goods or services. A company generally incurs R&D expenses in the process of finding and creating new products or services. It is an operating expense and can be deducted from a company's income taxes.


Highlights and Quick Summary

  • R&D Expenses for the quarter ending June 29, 2021 was $9.47 Million (a 58.8% increase compared to previous quarter)
  • Year-over-year quarterly R&D Expenses increased by 39.3%
  • Annual R&D Expenses for 2020 was $83.4 Million (a 517.97% increase from previous year)
  • Annual R&D Expenses for 2019 was $13.5 Million (a 119.61% increase from previous year)
  • Annual R&D Expenses for 2018 was $6.14 Million (a -4.95% decrease from previous year)
  • Twelve month R&D Expenses ending June 29, 2021 was $69.2 Million (a -17.94% decrease compared to previous quarter)
  • Twelve month trailing R&D Expenses increased by 69.89% year-over-year
Trailing R&D Expenses for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
$69.2 Million $84.4 Million $83 Million $40.8 Million
Visit stockrow.com/ORGS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical R&D Expenses of Orgenesis Inc.

Most recent R&D Expensesof ORGS including historical data for past 10 years.

Interactive Chart of R&D Expenses of Orgenesis Inc.

Orgenesis Inc. R&D Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $9.47 $5.96
2020 $47.01 $6.8 $24.61 $4.6 $83.38
2019 $4.75 $0.74 $1.71 $5.15 $13.49
2018 $4.44 $1.9 $0.79 $0.77 $6.14
2017 $0.5 $0.67 $0.74 $2.37
2016 $0.78 $0.49 $2.16
2015 $1.07
2014 $1.55
2013 $1.45
2012 $2.31

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.